Investigation of the effects of the toll-like receptor 4 pathway on immune checkpoint vista in pancreatic cancer
In this study, we investigated the relation of TLR4 and downstream pathways with immune-check point VISTA in pancreatic cancer proliferation. We initially collected pancreatic cancer-related datasets using the GEPIA2 and UALCAN databases. Based on this data obtained the effect of various concentrations and incubation times of naloxone were used on PANC-1 cells proliferation. A combination of naloxone and VISTA-siRNA were applied, and the effect of both naloxone and combinedtreatment on TLR4, Interleukin 1 receptor associated kinase 4 (IRAK4) and VISTA gene expression were analyzed in pancreatic cancer cells. As a result of...
Source: Investigational New Drugs - February 3, 2022 Category: Drugs & Pharmacology Source Type: research
Modulation of peritumoral fibroblasts with a membrane-tethered tissue inhibitor of metalloproteinase (TIMP) for the elimination of cancer cells
Conclusion. Peritumoral fibroblasts can be modulated with the TIMP for the elimination of cancer cells. As a novel anti-tumor strategy, our approach could potentially be used in combination with conventional chemo- and immunotherapies for a more effective cancer therapy. (Source: Investigational New Drugs)
Source: Investigational New Drugs - January 18, 2022 Category: Drugs & Pharmacology Source Type: research
Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer
In conclusion, carboplatin/nab-paclitaxel and concurrent thoracic radiotherapy show good tolerability and exhibit promising efficacy in elderly patients with locally advanced NSCLC. This trial was registered with the Japan Registry of Clinical Tri als on March 11, 2019 (trial no. jRCTs042180077). (Source: Investigational New Drugs)
Source: Investigational New Drugs - January 18, 2022 Category: Drugs & Pharmacology Source Type: research
A comprehensive analysis of different gene classes in pancreatic cancer: SIGLEC15 may be a promising immunotherapeutic target
Conclusion. Our study analyzed the relationships between 14 PC-related genes and pancreatic cancer from different angles, which may contribute to a better understanding of unsolved mystery in PC. (Source: Investigational New Drugs)
Source: Investigational New Drugs - January 18, 2022 Category: Drugs & Pharmacology Source Type: research
KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non ‐small cell lung cancer
Conclusion. This is the first comprehensive study to disclose that KAT2B is correlated with immune infiltrates and may serve as a novel biomarker predicting prognosis and response to immunotherapy in NSCLC. (Source: Investigational New Drugs)
Source: Investigational New Drugs - January 18, 2022 Category: Drugs & Pharmacology Source Type: research
Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer
SummaryParaneoplastic neurologic syndromes(PNSs) caused by immune checkpoint inhibitors(ICIs) is rare and requires clinicians to differentiate between disease progression and immune-related adverse effects(irAEs). We hereby report the case of immune-related myelitis accompanied by positive paraneoplastic autoantibodies following durvalumab treatment for extensive-stage small cell lung cancer (ES-SCLC). A 70-year-old Chinese woman with ES-SCLC was administered durvalumab with etoposid-platinum(EP) as first-line treatment. Four cycles after treatment with EP plus ICI, she developed immune-related myelitis with positive paran...
Source: Investigational New Drugs - January 18, 2022 Category: Drugs & Pharmacology Source Type: research
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies
Conclusions. Cediranib and selumetinib in combination on a continuous schedule was not tolerable, with patients experiencing cardiovascular and other DLTs. Intermittent schedules may be needed to establish a safe and tolerable combination of cediranib and selumetinib. (Source: Investigational New Drugs)
Source: Investigational New Drugs - January 18, 2022 Category: Drugs & Pharmacology Source Type: research
Author Correction: Antineoplastic activity of products derived from cellulose ‑containing materials: levoglucosenone and structurally‑related derivatives as new alternatives for breast cancer treatment
(Source: Investigational New Drugs)
Source: Investigational New Drugs - January 18, 2022 Category: Drugs & Pharmacology Source Type: research
Bendamustine versus chlorambucil in treatment of chronic lymphocytic leukaemia in China: a randomized, open-label, parallel-controlled, phase III clinical trial
Conclusion. In untreated Chinese patients with Binet stage B/C CLL, bendamustine induced the better objective response and resulted in longer progression-free survival than chlorambucil. Overall, these results validate the role of bendamustine as an effective and safe first-line therapy in this population. (Source: Investigational New Drugs)
Source: Investigational New Drugs - January 15, 2022 Category: Drugs & Pharmacology Source Type: research
Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study
Conclusions. For previously treated patients with Sq, the efficacy and safety of RAM/DOC therapy were confirmed in a real-world setting and were similar to non-Sq. (Source: Investigational New Drugs)
Source: Investigational New Drugs - January 13, 2022 Category: Drugs & Pharmacology Source Type: research
Biological evaluation of complexes of cyclopentadienyl M(CO)3+ (M = Re, 99mTc) with high blood–brain barrier penetration potential as brain cancer agents
SummaryTo address the major medical need for effective chemotherapeutics/diagnostics for brain cancer, in this work three cyclopentadienyl M(CO)3+ (M = Re,99mTc) complexes, which cross the blood-brain barrier (BBB) in high % and are designed to mimic the anticancer agent 2-phenylbenzothiazole, are in vitro and in vivo evaluated for anticancer action. The study includes cytotoxicity and uptake studies in cancer and healthy neuronal cell lines, mechanistic investigation of potential anticancer pathways, and biodistribution studies in mice bearing glioblastoma xenografts. The stable Re complexes exhibit selective uptake ...
Source: Investigational New Drugs - January 13, 2022 Category: Drugs & Pharmacology Source Type: research
IMB5036, a novel pyridazinone compound, inhibits hepatocellular carcinoma growth and metastasis
Conclusions These results collectively demonstrate IMB5036 can be a promising therapeutic candidate for patients with HCC. (Source: Investigational New Drugs)
Source: Investigational New Drugs - January 12, 2022 Category: Drugs & Pharmacology Source Type: research
Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model
Conclusions. Phenformin increased the percentages of LSK, MP, and MPP populations, but did not reduce disease burden in Jak2V617F-knockin mice. Additional studies are necessary to further understand the effects of phenformin on early hematopoietic progenitors. (Source: Investigational New Drugs)
Source: Investigational New Drugs - January 11, 2022 Category: Drugs & Pharmacology Source Type: research
Author Correction: Increased DKC1 expression in glioma and its significance in tumor cell proliferation, migration and invasion
(Source: Investigational New Drugs)
Source: Investigational New Drugs - January 10, 2022 Category: Drugs & Pharmacology Source Type: research
Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer
Conclusion. Apatinib combined with FOLFIRI for the first-line treatment of advanced unresectable mCRC showed good efficacy and safety. The baseline NLR was predictive of efficacy, and a low baseline NLR (HR: 0.2895, P = 0.0084) was associated with improved OS.Clinical Research Registration Number: ChiCTR1800015308. (Source: Investigational New Drugs)
Source: Investigational New Drugs - January 8, 2022 Category: Drugs & Pharmacology Source Type: research
